A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

第3相完了 NCT03524092

対象疾患	Ulcerative Colitis
相	第3相
スポンサー	Eli Lilly and Company
ステータス	完了
参加者数	1,328 名
介入（薬剤）	Mirikizumab SC, Mirikizumab IV, Placebo SC
開始日	2018年10月19日
完了日	2021年11月3日
結果公開日	2022年11月25日

概要

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).

Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders)

Week 40 · percentage of participants

Maintenance Period: Miri IR - PBO SC	25.1 percentage of participants
Maintenance Period: Miri IR - 200 mg Miri SC	49.9 percentage of participants

p-value	<0.001
Risk Difference (RD)	23.2 (95% CI 15.2–31.2)

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
GI Permeability Change in Response to Aquamin® — James Varani
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。

English 한국어 日本語中文 Русский